News

Latest News:

mc2_news-image-icon-07

MC2 Therapeutics appoints Christopher S. Billis as Chief Commercial Officer

POSTED: October 25, 2018

Copenhagen, October 25th, 2018 – MC2 Therapeutics A/S, a clinical-stage dermatology and eye care company today announced that it has appointed Christopher S. Billis, an experienced healthcare executive within the ...

READ FULL ARTICLE >

MC2 Therapeutics A/S announces topline results showing a favorable safety profile and reduction in corneal staining for MC2-03 in dry eye patients with moderate to severe keratitis

POSTED: October 23, 2018

 

  • Active MC2-03 eye drop treatment resulted in a strong clinical improvement in severe dry eye patients over control arms both on CFS response (p=0.0090) and mean change from Baseline to ...

    READ FULL ARTICLE >

mc2_news-image-icon-04

MC2 Therapeutics A/S announces positive top-line results from Phase 3 clinical trial comparing MC2-01 Cream to Taclonex® in adults with psoriasis

POSTED: August 21, 2018

MC2-01 Cream demonstrates statistically significant superiority in both treatment success and patient reported treatment convenience compared to Taclonex® Topical Suspension. Both primary and secondary endpoints were met and a submission ...

READ FULL ARTICLE >

mc2_news-image-icon-07

MC2 Therapeutics A/S announces completion of recruitment in US Phase 3 trial in Psoriasis Vulgaris

POSTED: April 2, 2018

  • Topline results are expected in Q3 2018

Copenhagen, April 2nd, 2018 – MC2 Therapeutics A/S, a clinical-stage dermatology and eye care company today announced that the patient enrollment for the Phase ...

READ FULL ARTICLE >

Events:

February 28th - 29th, 2024

MC2 Therapeutics to present at the 17th Annual European Life Sciences CEO Forum

READ MORE >

November 14th - 16th, 2023

Meet MC2 at Jefferies London Healthcare Conference

READ MORE >

May 15th - 16th, 2023

MC2 Therapeutics to present at Bio€quity Europe 2023

READ MORE >

February 7th, 2023

MC2 Therapeutics to present at the BIO CEO & Investor Conference in NYC

READ MORE >

January 9th - 12th, 2023

J.P. Morgan Healthcare Conference 2023 (San Francisco)

READ MORE >

January 8th, 2023

MC2 Therapeutics to present at the Dermatology Summit 2023 in San Francisco

READ MORE >

December 7th, 2022

MC2 Therapeutics to present at Carnegie’s Next Generation Nordic Life Science Champions Seminar 2022

READ MORE >

November 15th - 17th, 2022

MC2 Therapeutics attends the Jefferies London Healthcare Conference

READ MORE >

February 28th, 2022

MC2 exposure at PCMA Business Forum 2022

READ MORE >

August 11th, 2021

MC2 Therapeutics is proud to support National Psoriasis Action Month

READ MORE >

July 23, 2021

MC2 Therapeutics supports World Sjögren’s Day

READ MORE >